---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-001672"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2025-01-16T23:59:59+00:00"
generated_at: "2026-05-27T23:55:10.178272+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Esperion provides FY2025 expense guidance at J.P. Morgan Conference

## Summary
- R&D expenses expected $55M to $65M for FY2025.
- SG&A expenses expected $160M to $170M for FY2025.
- Total operating expenses expected $215M to $235M for FY2025.
- Guidance announced at 43rd Annual J.P. Morgan Healthcare Conference on Jan 15, 2025.

## SEC filing metadata
- accession: 0001628280-25-001672
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2025-01-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828025001672/0001628280-25-001672-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828025001672/espr-20250115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-001672
- JSON: https://secwatch.observer/filing/0001628280-25-001672.json
- Plain text: https://secwatch.observer/filing/0001628280-25-001672.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.